Survival in the prostate cancer prevention trial.

The New England journal of medicine ·Vol. 369 ·No. 20 ·2013-00-14 ·Pages 1968

Tangen CM, Goodman PJ, Thompson IM

Abstract

暂无摘要

MeSH Terms

5-alpha Reductase Inhibitors/therapeutic use Finasteride/therapeutic use Humans Male Prostatic Neoplasms/prevention & control

Chemicals

5-alpha Reductase Inhibitors Finasteride

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Tangen Catherine M

Goodman Phyllis J

Thompson Ian M

References (4)

4 references, click to expand

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Cancer Prev Res (Phila). 2008 Aug;1(3):174-81 PMID: 19138953
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
N Engl J Med. 2011 Jul 14;365(2):97-9 PMID: 21675880
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
Cancer. 2013 Feb 1;119(3):593-601 PMID: 22893105
Long-term survival of participants in the prostate cancer prevention trial.
N Engl J Med. 2013 Aug 15;369(7):603-10 PMID: 23944298

Article Info

Journal

The New England journal of medicine

Abbr.

N Engl J Med

ISSN

1533-4406

DOI

10.1056/NEJMc1311498

Published

2013-00-14

Pages

1968

Language

English

Region

United States

NLM ID

0255562

PMCID

PMC4927191

Subset

Grants

NCI NIH HHS · UM1 CA182883 · United States

Corrections

CommentOn

PMID: 23944298

CommentOn

PMID: 24224633

CommentOn

PMID: 24224634

External Links

PubMed source DOI: 10.1056/NEJMc1311498 PMC Full Text View journal details

Analysis Services

Survival in the prostate cancer prevention trial.

Contact

WeChat Official Account